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Abstract: 
Autism spectrum disorder (ASD) encompasses a spectrum of pervasive neuropsychiatric 
disorders characterised by deficits in social interaction, communication, unusual and 
repetitive behaviour. The aetiology of ASD is believed to involve complex interactions 
between genetic and environmental factors; it can be further classified as syndromic or non-
syndromic, according to whether it is the primary diagnosis or secondary to an existing 
condition where both common and rare genetic variants contribute to the development of 
ASD or are clearly causal.  
 
The prevalence of ASD in children is increasing with higher rates of diagnosis and an 
estimated 1 in 100 affected in the UK.i Given that heritability is a major contributing factor, 
we aim to discuss research findings to-date in the context of a high risk autism candidate 
gene, SHANK3 (SH3 and multiple ankyrin repeat domain 3), with its loss resulting in 
synaptic function disruption. 
We present a 10-year old patient with a pathogenic de novo heterozygous c.1231delC, 
p.Arg411Val frameshift variant in SHANK3. He presented with severe autism, attention 
deficit hyperactivity disorder and pathological demand avoidance, on a background of 
developmental impairment and language regression.  
The number of genes associated with autism is ever increasing. It is a heterogeneous group of 
disorders with no single gene conferring pathogenesis in the majority of cases.  Genetic 
abnormalities can be detected in approximately 15% of ASD and these range from copy 
number variants in 16p11.2 and 15q13.2q13.3 to several well-known genetic disorders 
including Tuberous Sclerosis and Fragile X syndrome.  Further high confidence autism genes 
include but are not limited to:  NRXN, NLGN 3, NLGN 4, SHANK 2 and SHANK3. 
Introduction: 
Autism has a worldwide childhood prevalence of approximately 1 in 160 childrenii and has 
become a frequent reason for referral to paediatric genetic services. Due to its clinical and 
genetic heterogeneity, the underlying cause for ASD remains unclear. However, advances in 
genetic testing have led to the discovery of several high risk autism candidate genes.iii 
 
Here, we focus our attention on one of these high risk genes, SHANK3. This gene is strongly 
expressed in the cerebral cortex and cerebellum and encodes a scaffold protein involved in 
the postsynaptic density (PSD) of excitatory synapses.iv  
 
It is widely known that microdeletions of 22q13 region involving SHANK3 are responsible 
for the clinically recognizable Phelan-McDermid syndrome (PMS)v characterised by global 
developmental delay, intellectual disability (ID), absent or severely delayed speech, autism 
spectrum disorder, hypotonia, and distinctive facial dysmorphic features. However, 
SHANK3 variants have also been reported in individuals with autism and/or intellectual 
disability.vivii 
 
The SHANK3 protein is a crucial component of the postsynaptic density that takes part in the 
neuroligin-neurexin interaction at glutamate synapses. Genetic studies show that the 
neurexin-neuroligin (NRXN-NLGN) pathway genes contribute susceptibility to ASD, which 
include cell adhesion molecules NLGN3, NLGN4 (also named NLGN4X), NRXN1 and 
scaffolding proteins SHANK2 and SHANK3 viii 
 
 
 
Clinical report: 
This 10-year old boy was the fifth pregnancy to healthy non-consanguineous, Caucasian 
parents. There had been two miscarriages prior to this pregnancy.  He was born at term with a 
birth weight of 4.5kg. There was bleeding throughout pregnancy but antenatal scans were 
normal. There was an increased risk of Down syndrome reported on antenatal screening.  
 
In terms of his development, he could sit unaided at 7 months and walked at 10 months.  He 
had multiple words at 11 months, but subsequently lost speech until the age of 4. At his 2 
year check, there were concerns regarding poor eye contact and limited speech. Following a 
clinical psychologist assessment, he fulfilled the criteria for severe autism.  His parents 
reported episodes consistent with absence seizures at this stage too. 
 
At age 5, he was attending mainstream school with additional support of two teaching 
assistants. Communication and social skills were noted to be poor.  In terms of behaviour, 
frustration and violent traits were noted. He was late to develop imaginary play and weakness 
in social interaction with peers was noted.  At age 10, he was attending a special needs 
school. He was exhibiting pathological demand avoidance and complex social impairments.  
 
Clinical examination did not reveal any dysmorphic features (Figure 1). 
Investigations so far have included: an EEG which was unremarkable; Cytogenetics showing 
a normal male karyotype (46XY) and Fragile X testing which was also negative. A 
microarray revealed no clinically significant imbalances, after which the patient was enrolled 
in the Deciphering Developmental Delay (DDD) study which identified a de novo 
heterozygous c.1231delC, p.Arg411Val frameshift variant in SHANK3. 
 
 Discussion: 
Patients with ASDs and ID carrying SHANK3 variants have been described in the literature. 
Several papers have reported SHANK3 variants in ASD patients, consisting of copy number 
variants,ix  point variants,xxixiixiii and polymorphisms.xiv 
De novo pathogenic variants in SHANK 3 accounted for 1.4% and 0.75% of ASD cohort 
subjects in studies conducted in 2007 by Durand et al and Moessner et al respectively. xv 
Bozdagi et al in 2011 reported that the loss of one copy of SHANK3 correlates with 
behavioural issues reproducing most of the ASD traits, such as deficits in social interaction, 
social communication, and compulsive/repetitive actions.xvi 
 
Buccuto et al in 2013 assessed the prevalence of variants in SHANK3 in two cohorts of 
patients with different subtypes of ASD. xvii  Pathogenic alterations in SHANK3 were found in 
2.3% of cases (5 patients): one ௗNEGHOHWLRQHQFRPSDVVLQJWKHSHANK3 gene, two 
frameshift variants leading to premature stop codons, one missense variant (p.Pro141Ala), 
and one splice site variant (c.1820-4G>A).  It was also noted that in the cases of 
the SHANK3 deletion and frameshift variants, the patients showed some degree of speech or 
developmental delay in association with autistic traits, similar to the patient we report here.   
It is plausible that the overall level of functional SHANK3 protein is lower as a result of these 
variants compared to cases with different types of variants.  
 
Nemirovsky et al in 2015 described three siblings with ASD, intellectual disability and 
absence of language to have germline mosaicism for a heterozygous deletion of a cytosine in 
the exon 21 of the SHANK3 gene. This resulted in the substitution of five amino acids 
followed by a premature stop codon (NM_033517:c.3259_3259delC, p.Ser1088Profs*6).xviii 
 Terrone et al in 2017 went on to describe a family with four members carrying an interstitial 
microdeletion within SHANK3 leading to intellectual disabilityxix. This involved a mother and 
three children and was the first report of a familial microdeletion. Each carrier in this family 
presented with symptoms of autism.  
 
However, Liu et al in 2013 did not find any significant association between four high risk 
genes (NLGN3, NLGN4, SHANK 2 and SHANK 3) and ASD cases in a Chinese population. xx 
This perhaps highlights the heterogeneous nature of ASD, variability of gene function in 
different populations but also the role of environmental factors and their potential 
contribution to the phenotype.xxi  
Conclusion 
Autism spectrum disorders (ASD) describes a heterogeneous spectrum of disorders with no 
single causal gene conferring pathogenicity in the majority of cases. The disease process 
comprises great genetic and phenotypic complexity.  
Our report details a 10-year old boy with a de novo heterozygous c.1231del, p.Arg411Val 
frameshift variant in SHANK3, a high risk candidate autism gene. We report significant 
speech delay and seizures as an association with this phenotype.  
Our case findings appear to be in line with previous findings for SHANK3 and other genes 
involved in the neurexin-neuroligin complex. Further case reports of this nature will continue 
to expand the phenotype and understand the variable expressivity of SHANK3. 
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